Trials / Withdrawn
WithdrawnNCT04351919
Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)
Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+), inTunisia
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Abderrahmane Mami Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study will assess the number of patients who become asymptomatic from clinical signs of COVID19 and will assess the efficacy of Hydroxychloroquine (HCQ) and Azithromycine effects on paucisymptomatic patients with ou without co-morbidities
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hydroxychloroquine | 400mg per day during 10 days |
| DRUG | Azithromycin | 500 mg per day during 5 days |
Timeline
- Start date
- 2020-05-05
- Primary completion
- 2020-07-15
- Completion
- 2020-07-15
- First posted
- 2020-04-17
- Last updated
- 2020-08-28
Locations
1 site across 1 country: Tunisia
Source: ClinicalTrials.gov record NCT04351919. Inclusion in this directory is not an endorsement.